Total Payments
$16,592
2024 Payments
$2,561
Companies
55
Transactions
894
Medicare Patients
4,229
Medicare Billing
$563,601
Payment Breakdown by Category
Food & Beverage$14,897 (89.8%)
Travel$1,463 (8.8%)
Research$150.00 (0.9%)
Education$52.40 (0.3%)
Consulting$28.35 (0.2%)
Gifts$1.07 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $14,897 | 886 | 89.8% |
| Travel and Lodging | $1,463 | 3 | 8.8% |
| Unspecified | $150.00 | 1 | 0.9% |
| Education | $52.40 | 2 | 0.3% |
| Consulting Fee | $28.35 | 1 | 0.2% |
| Gift | $1.07 | 1 | 0.0% |
Payments by Type
General
$16,442
893 transactions
Research
$150.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $4,453 | 252 | $0 (2024) |
| Celgene Corporation | $2,251 | 38 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $2,097 | 125 | $0 (2024) |
| PFIZER INC. | $1,041 | 73 | $0 (2024) |
| Janssen Biotech, Inc. | $938.88 | 75 | $0 (2024) |
| Allergan, Inc. | $512.78 | 40 | $0 (2020) |
| IRONWOOD PHARMACEUTICALS, INC | $501.35 | 24 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $494.93 | 36 | $0 (2024) |
| Gilead Sciences, Inc. | $473.09 | 15 | $0 (2022) |
| Valeant Pharmaceuticals North America LLC | $402.39 | 20 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,561 | 146 | ABBVIE INC. ($1,051) |
| 2023 | $2,138 | 122 | ABBVIE INC. ($813.68) |
| 2022 | $1,801 | 101 | ABBVIE INC. ($712.66) |
| 2021 | $544.67 | 28 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($170.62) |
| 2020 | $665.04 | 40 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($171.89) |
| 2019 | $2,171 | 141 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($522.40) |
| 2018 | $4,210 | 168 | Celgene Corporation ($1,817) |
| 2017 | $2,501 | 148 | AbbVie, Inc. ($587.72) |
All Payment Transactions
894 individual payment records from CMS Open Payments — Page 1 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $28.89 | General |
| Category: VIROLOGY | ||||||
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.66 | General |
| Category: Gastroenterology | ||||||
| 12/18/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $9.25 | General |
| Category: VIROLOGY | ||||||
| 12/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: Immunology | ||||||
| 12/16/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: Gastroenterology | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $22.03 | General |
| Category: Gastroenterology | ||||||
| 11/25/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $32.51 | General |
| Category: VIROLOGY | ||||||
| 11/20/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.52 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $4.29 | General |
| Category: VIROLOGY | ||||||
| 11/19/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/19/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $11.43 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: Immunology | ||||||
| 11/12/2024 | ABBVIE INC. | CREON (Drug), VIBERZI, LINZESS | Food and Beverage | In-kind items and services | $13.48 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/06/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/06/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: Gastroenterology | ||||||
| 10/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $11.23 | General |
| Category: Gastroenterology | ||||||
| 10/28/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $32.96 | General |
| Category: Immunology | ||||||
| 10/24/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: IMMUNOLOGY | ||||||
| 10/23/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $31.88 | General |
| Category: VIROLOGY | ||||||
| 10/23/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $2.43 | General |
| Category: VIROLOGY | ||||||
| 10/22/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: GASTROENTEROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $150.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 982 | 1,365 | $655,559 | $134,415 |
| 2022 | 12 | 1,040 | 1,390 | $682,967 | $143,482 |
| 2021 | 13 | 1,125 | 1,470 | $748,156 | $146,557 |
| 2020 | 12 | 1,082 | 1,462 | $727,630 | $139,147 |
Total Patients
4,229
Total Services
5,687
Medicare Billing
$563,601
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 412 | 776 | $211,848 | $70,434 | 33.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 55 | 57 | $46,569 | $10,146 | 21.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 137 | 147 | $131,712 | $8,970 | 6.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 37 | 39 | $43,056 | $8,158 | 18.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 78 | 78 | $32,370 | $7,970 | 24.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 59 | 59 | $61,596 | $7,359 | 11.9% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 55 | 58 | $53,882 | $6,794 | 12.6% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 26 | 26 | $21,268 | $3,657 | 17.2% |
| 76981 | Ultrasound scan of organ tissue for measuring elasticity | Office | 2023 | 40 | 40 | $10,200 | $3,116 | 30.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 42 | $7,812 | $2,744 | 35.1% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 12 | 12 | $9,816 | $2,200 | 22.4% |
| 45384 | Removal of polyps or growths of large bowel using a flexible endoscope with electrical cautery | Facility | 2023 | 17 | 19 | $22,154 | $2,075 | 9.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $3,276 | $792.25 | 24.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 394 | 724 | $197,794 | $67,854 | 34.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 113 | 113 | $46,895 | $14,031 | 29.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 51 | 52 | $57,408 | $10,654 | 18.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 75 | 76 | $79,344 | $9,916 | 12.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 48 | 48 | $39,216 | $8,931 | 22.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 127 | 136 | $121,856 | $8,711 | 7.1% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2022 | 53 | 59 | $54,811 | $6,627 | 12.1% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 43 | 43 | $35,174 | $6,029 | 17.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 86 | 89 | $16,641 | $5,843 | 35.1% |
| 45384 | Removal of polyps or growths of large bowel using a flexible endoscope with electrical cautery | Facility | 2022 | 15 | 15 | $17,490 | $1,905 | 10.9% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 17 | 17 | $11,424 | $1,634 | 14.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 18 | 18 | $4,914 | $1,347 | 27.4% |
About Dr. Mark Eisner, MD
Dr. Mark Eisner, MD is a Gastroenterology healthcare provider based in Zephyrhills, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1902815103.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Eisner, MD has received a total of $16,592 in payments from pharmaceutical and medical device companies, with $2,561 received in 2024. These payments were reported across 894 transactions from 55 companies. The most common payment nature is "Food and Beverage" ($14,897).
As a Medicare-enrolled provider, Eisner has provided services to 4,229 Medicare beneficiaries, totaling 5,687 services with total Medicare billing of $563,601. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Zephyrhills, FL
- Active Since 08/05/2006
- Last Updated 08/25/2021
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1902815103
Products in Payments
- Ozanimod (Drug) $1,817
- XIFAXAN (Drug) $1,810
- LINZESS (Drug) $1,006
- XELJANZ (Drug) $993.25
- MAVYRET (Drug) $897.27
- Mavyret (Drug) $673.08
- STELARA (Biological) $650.23
- Creon (Drug) $616.70
- SKYRIZI (Biological) $552.76
- RINVOQ (Biological) $505.78
- ZEPOSIA (Drug) $412.42
- OCALIVA (Drug) $378.73
- Linzess (Drug) $321.22
- ZENPEP (Drug) $317.86
- APRISO (Drug) $301.34
- CREON (Drug) $271.82
- VIBERZI (Drug) $262.50
- RELISTOR (Drug) $256.34
- Epclusa (Drug) $219.64
- Trulance (Drug) $208.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Zephyrhills
Tawfik Chami, Md, MD
Gastroenterology — Payments: $27,028
Gastroenterology $27,028
Dr. Soloman Singh, Md, MD
Gastroenterology — Payments: $12,908
Gastroenterology $12,908
Dr. Yawer Nensey, Md, MD
Gastroenterology — Payments: $9,602
Gastroenterology $9,602
Maher Salam, M.d, M.D
Gastroenterology — Payments: $4,778
Gastroenterology $4,778
Dr. Thomas John, Md, MD
Gastroenterology — Payments: $2,506
Gastroenterology $2,506
Dr. Kozhimala John, Md, MD
Gastroenterology — Payments: $1,251
Gastroenterology $1,251